Australia's most trusted
source of pharma news
Tuesday, 02 June 2026
Posted 2 June 2026 AM
Three PBS-listed drugs which earned around $168 million combined in 2025 face generic competition for the first time from June meaning a 25 per cent statutory reduction in price.
All the competing brands were registered on the ARTG within the last 10 months.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.